

# PREDIABETES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS: PREVALENCE AND CLINICAL SIGNIFICANCE

C. García-Figueras<sup>1</sup> M. Cayón<sup>2</sup>, P. Bancalero<sup>1</sup>, A. Terrón<sup>1</sup>.

Infectious Diseases Unit<sup>1</sup>. Endocrinology and Nutrition Unit<sup>2</sup>. Hospital S.A.S. Jerez de la Frontera, Jerez de la Fra., Spain.

## INTRODUCTION

**Changes at the glucose metabolism are common in patients with HIV infection on antiretroviral treatment. Although the relevance of disorders in glucose metabolism is well recognized in HIV-infected individuals, the potential clinical relevance of prediabetes in this population has been little studied. The aims of this study were to determine the prevalence of prediabetes in a cohort of HIV-infected patients on long term highly active antiretroviral therapy (HAART) and to assess whether this condition involves the appearance of particular clinical and metabolic features.**

## METHODS/DESIGN

### Observational study.

105 HIV-positive individuals (85,7% men, mean age:  $46 \pm 6,5$  years) were enrolled.

Prediabetes was defined using established ADA criteria: Fasting plasma glucose (FPG) 100 to 125 mg/dL or 2-h plasma glucose in the 75-g OGTT 140 to 199 mg/dL or HbA1c 5,7-6,4%.

Data related to HIV infection, HCV co-infection and anthropometric and metabolic parameters were recorded (tables 1 and 2).

**Table 1:**  
**Epidemiological variables (n = 105)**

Gender Male/Female (%)	85,7/14,3
Age (years)	$46 \pm 6,5$
HCV/HIV co-infection (%)	55,2
BMI (Kg/m <sup>2</sup> )	$24,9 \pm 4,7$
Waist circumference (cm)	$89,2 \pm 13,2$
Waist to hip ratio	$0,9 \pm 0,1$
Prediabetes	41%

**Table 2:**  
**Biochemical characteristics (n = 105)**

FPG (mg/dL)	$94,1 \pm 10,7$
Fasting insulin ( $\mu$ U/mL)	$10,9 \pm 8,7$
HOMA-IR	$4,2 \pm 3,1$
LDLc (mg/dL)	$116,6 \pm 36,8$
HDLc (mg/dL)	$50,4 \pm 17,8$
Triglycerides (mg/dL)	$145,9 \pm 74,8$
CD4+/mm <sup>3</sup>	$623,1 \pm 322,6$

## RESULTS


Prevalence of prediabetes was not significantly higher among HCV/HIV patients (figure 1).

When compared to normoglycemic controls, patients with prediabetes had significantly higher waist-to-hip ratio, higher FPG levels, higher basal insulin and higher HOMA-IR (table 3).

HCV/HIV with prediabetes were mostly men and had significantly lower LDLc levels and lower total cholesterol as compared to prediabetic HIV group (table 4).

**Figure 1:**

**Prevalence of prediabetes among HIV patients with or without HCV co-infection**



**Table 3: Prediabetes vs normoglycemic**

	Prediabetes	Normoglycemic	p
Gender: males (%)	83,7	87,1	NS
Age (years)	$47,2 \pm 5,7$	$45,1 \pm 7$	NS
BMI (Kg/m <sup>2</sup> )	$25,4 \pm 5,4$	$25,4 \pm 4,2$	NS
Waist circumference (cm)	$95,4 \pm 7,7$	$95,9 \pm 7,6$	NS
Waist to hip ratio	$0,96 \pm 0,11$	$0,91 \pm 0,1$	<b>&lt;0,001</b>
Systolic blood pressure (mm Hg)	$123,4 \pm 15,8$	$119,8 \pm 14,6$	NS
Diastolic blood pressure (mm Hg)	$78,5 \pm 7,2$	$78,7 \pm 8,9$	NS
FPG (mg/dL)	$99,4 \pm 9,9$	$90,4 \pm 9,6$	<b>&lt;0,001</b>
HbA1c (%)	$5,8 \pm 0,3$	$5,2 \pm 0,3$	NS
Fasting insulin ( $\mu$ U/mL)	$14,1 \pm 11,5$	$8,6 \pm 5,1$	<b>0,005</b>
HOMA-IR	$4,4 \pm 0,9$	$1,9 \pm 1,2$	<b>0,013</b>
Total Cholesterol (mg/dL)	$194,8 \pm 42,2$	$182,4 \pm 41,6$	NS
LDLc (mg/dL)	$124,6 \pm 34,5$	$111,3 \pm 37,6$	NS
HDLc (mg/dL)	$49,4 \pm 13,9$	$51,1 \pm 20$	NS
Triglycerides (mg/dL)	$152,6 \pm 79$	$141,2 \pm 72,1$	NS
CD4+/mm <sup>3</sup>	$678,5 \pm 380,5$	$584,7 \pm 272,2$	NS

NS: not significant

**Table 4: Patients with prediabetes classified according to HCV co-infection**

	HCV/HIV	HIV	p
Gender: males (%)	100	61,1	<b>0,001</b>
Age (years)	$48,1 \pm 4,9$	$46 \pm 6,6$	NS
BMI (Kg/m <sup>2</sup> )	$25,3 \pm 6,1$	$25,5 \pm 4,5$	NS
Waist circumference (cm)	$91,7 \pm 14,6$	$91,3 \pm 14,1$	NS
Waist to hip ratio	$0,97 \pm 0,1$	$0,94 \pm 1,1$	NS
Systolic blood pressure (mm Hg)	$122,6 \pm 18,2$	$124,5 \pm 12$	NS
Diastolic blood pressure (mm Hg)	$76,5 \pm 7,7$	$81 \pm 5,6$	NS
FPG (mg/dL)	$100,7 \pm 10,4$	$97,7 \pm 9,3$	NS
HbA1c (%)	$5,8 \pm 0,3$	$5,8 \pm 0,3$	NS
Fasting insulin ( $\mu$ U/mL)	$13 \pm 8,3$	$15,1 \pm 3,5$	NS
HOMA-IR	$4,9 \pm 1,5$	$3,9 \pm 0,9$	NS
Total Cholesterol (mg/dL)	$180,4 \pm 34,7$	$213,9 \pm 44,6$	<b>0,009</b>
LDLc (mg/dL)	$113,2 \pm 27,2$	$139,9 \pm 37,7$	<b>0,013</b>
HDLc (mg/dL)	$48,4 \pm 11,2$	$50,7 \pm 16,9$	NS
Triglycerides (mg/dL)	$146,8 \pm 87,4$	$168,7 \pm 67,1$	NS
CD4+/mm <sup>3</sup>	$639,5 \pm 348,3$	$213,9 \pm 44,6$	NS

NS: not significant

## CONCLUSIONS

- HIV patients on long-term HAART are at risk to develop prediabetes, especially if abdominal obesity is present thus, measurements of HOMA-index and waist-to-hip ratio should be routinely done.
- The worst serum lipid profile in prediabetic HIV without HCV co-infection suggests that this parameter deserves special attention in these individuals.